3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
8
Terminated
4
Recruiting
2
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
2
Conditions
Neoplasms
5
Multiple Myeloma
3
Hematologic Neoplasms
3
Thyroid Cancer, Papillary
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Carcinoma, Anaplastic
1
Rare Tumor
1
Ovarian Neoplasms
1
Lymphoproliferative Disorders
1
Leukemia, Hairy Cell
1
Laryngeal Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Cancer Metastatic
1
Adenocarcinoma, Follicular
1
Interventions
pembrolizumab
49
Specimen Handling
29
Magnetic Resonance Spectroscopy
25
Biopsy
25
Radiosurgery
17
Gemcitabine
17
Nivolumab
16
Cyclophosphamide
14
Cisplatin
14
Paclitaxel
13
Carboplatin
13
Bevacizumab
13
Leucovorin
11
Irinotecan
11
Fluorouracil
11
Drug Therapy
11
Taxes
10
Radiotherapy
10
Oxaliplatin
10
Capecitabine
10
trastuzumab deruxtecan
9
fludarabine
9
cemiplimab
8
Doxorubicin
8
Cetuximab
8
abemaciclib
7
Trastuzumab
7
Pemetrexed
7
Fulvestrant
7
Docetaxel
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm Metastasis
×
Vemurafenib
×
Clear all
NCT05525858
2025-04-27
KOSMOSII
Seoul National University Bundang Hospital
Recruiting
1,000 enrolled
NCT04817956
2024-02-29
IMPRESS-N
Oslo University Hospital
Phase 2
Recruiting
3,000 enrolled